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DDP-induced cytotoxicity is not influenced by p53 in
nine human ovarian cancer cell lines with different
p53 status
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Summary Nine human ovarian cancer cell lines that express wild-type (wt) or mutated (mut) p53 were used to evaluate the cytotoxicity
induced by cisplatin (DDP). The concentrations inhibiting the growth by 50% (IC50) were calculated for each cell line, and no,differences were
found between cells expressing wt p53 and mut p53. Using, for each cell line, the DDP IC509 we found that these concentrations were able to
induce an increase in p53 levels in all four wt-p53-expressing cell lines and in one out of five mut-p53-expressing cell lines. WAF1 and
GADD45 mRNAs were also increased by DDP treatment, independently ofthe presence of a wt p53. Bax levels were only marginally affected
by DDP, and this was observed in both wt-p53- and mut-p53-expressing cells. DDP-induced apoptosis was evident 72 h after treatment, and
the percentage of cells undergoing apoptosis was slightly higherforwt-p53-expressing cells. However, at doses nearthe IC50, the percentage
of apoptotic cells was less than 20% in all the cell lines investigated. We conclude that the presence of wt p53 is not a determinant for the
cytotoxicity induced by DDP in human ovarian cancer cell lines.
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Cisplatin (DDP) is one of the most effective agents in the treat-
ment ofovarian cancer, in which it has shown activity either alone
or in combination with other chemotherapeutic agents (Ozols et al,
1991; Cannistra, 1993; NIH, 1994). Its mechanism of action
involves the interaction and alkylation of DNA, which results in
the formation of monoadducts, interstrand and intrastrand
crosslinks (Eastman 1983; Sherman et al, 1987). These lesions,
which are thoughttobe responsible forthecytotoxicity induced by
DDP, are mostly repaired through a nucleotide excision repair
mechanism (Hoeijmakers, 1993, 1994; Damia et al, 1996). In this
regard, the tumour-suppressor protein p53 has been shown to be
implicated in DNA repair by either increasing the levels of
p21WAF1 or by interacting with nucleotide excision repair
proteins (Kastan et al, 1991; Lane, 1992; Wang et al, 1994, 1995).
Considering that in more than 50% of human tumours the p53
gene is mutated (Greenblatt etal, 1994), itis important to define its
role in determining the sensitivity of cancer cells to anti-cancer
agents. Different studies have reported the effects ofthe presence
of mutated p53 on the response of cells to DDP treatment. There
are data supporting that the presence ofa wt p53 confers a greater
sensitivity orresistance to DDP, depending on the cell types inves-
tigated (Brown et al, 1993; Fan et al, 1995; Gjerset et al, 1995;
Perego et al, 1996).
Additional data have shown that in some cell types DDP-
induced cytotoxicity is independent on the presence of wt or
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mutated p53 (Graniela Sire et al, 1995; Vikhanskaya et al, 1995;
Wosikowski et al, 1995).
In this report, we analysed the DDP-induced cytotoxicity in
human ovarian cancercell lines expressing wt ormutated p53. The
data were analysed together with the effects of DDP on the levels
of p53 and of p53-downstream genes (WAF], GADD45 and bax)
as well as with the DDP-induced apoptosis in these cell lines.
MATERIALS AND METHODS
Cell lines and treatment
Four human ovarian cancer cell lines expressing wild-type p53,
i.e. PA-1, IGROV-1, A2780 and A2774, and five expressing no
p53 or mutated p53, i.e. OVCAR-3 (mutation at codon 248, R to
Q), OVCAR-5 (insertion of 3 bp at 224), OVCAR-8 (deletion
126-132), SW626 (mutation at codon 262 G to V) and SKOV-3
(deletion), were used. They were maintained in RPMI 1640
supplemented with 10% fetal calf serum (FCS). The p53 status
was determined for A2774 and SW626 cell lines by polymerase
chain reaction (PCR) amplifications and sequencing ofexons 5-8.
In these experiments, A2780 and OVCAR-3 cells were used as
controls and their status was confirmed.
Clones were obtained from the p53-null line SKOV-3 upon
transfection with the temperature-sensitive murine p53 (SK23)
(Vikhanskaya et al, 1994) or with the human wild-type p53 under
the control of tetracycline (SKT4) after selection in G418-
containing medium (500,g ml-').
Cytotoxicity was evaluated using the MTT test in 96-well plates
(Nunc) at different times after treatment with different concentra-
tions ofDDP.
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Figure 1 IC50 values of DDP in the different ovarian cancer cell lines. The
upper part shows a graphic representation of the IC05 values according to the
status of p53
IC50 values were calculated at 72 h of recovery after DDP treat-
ment (24 h).
Northern blot analysis
Total RNA was extracted from untreated or DDP-treated cells (after
1, 6 or 24 h of treatment) using the guanidine/caesium chloride
gradient method (Sambrook etal, 1989). Afterfractionation through
1% agarose-formaldehyde gels, RNA was blotted on nylon
membranes and hybridized with WAFI, GADD45 and bax.
Each c-DNA was 32p labelled using a Rediprime kit (Amersham).
Hybridizations were performed at 42°C for 16 h, followed by two
washes at room temperature with 2 x standard saline citrate (SSC)
(150 mm sodium chloride-15 mm sodium citrate) and one wash at
65°C in 2 x SSC-l% sodium dodecyl sulphate (SDS). GADD45
and WAFI probes were obtained by PCR using primers deduced
from the published sequence as described (Vikhanskaya et al, 1994).
Western blot analysis
Total cell extracts were prepared from untreated or DDP-treated
cells, after 6 or 24 h oftreatment, according to standard procedures.
Twenty micrograms of proteins for each sample were elec-
trophoresed through 12% SDS-polyacrylamide gels and trans-
ferred to nitrocellulose. Filters were hybridized with monoclonal
antibody against p53 (DO-1, Santa Cruz Biotechnology) and were
detected with the electrochemiluminescence (ECL) system after
addition ofanti-mouse IgG (Santa Cruz Biotechnology).
Evaluation of apoptosis
The staining with DAPI was used to detect apoptotic cells. Cells
were seeded on glass coverslips in 24-well plates (25 000 cells
ml-') and treated with DDP at the respective IC50. After 24, 48 and
SKOV-3
Figure 2 Western blotting showing the change in p53 levels in the different
human ovarian cancer cell lines after 6 and 24 h of treatment with DDP at the
IC50 values reported in Figure 1
72 h, cells were fixed in 70% ethanol, air-dried and stained with
DAPI and sulphorhodamine (Darzynkiewicz et al, 1992). After
washes in phosphate-buffered saline (PBS), coverslips were
mounted in Mowiol 4-88 (Hoechst, Frankfurt/Main, Germany)
and observed in a Zeiss Axiophot photomicroscope equipped for
epifluorescence (Carl Zeiss, Oberkochen, Germany). Fluorescent
images were recorded on Kodak films.
Filter binding assay
The method previously described (Bertrand et al, 1995) was used.
Briefly, 5 x 105 cells prelabelled with 0.02 iCi ml-' [14C]thymidine
were loaded onto PVC filters, washed with PBS and lysed with
5 ml of a solution containing 0.2% sodium sarkosyl, 2 M sodium
chloride, 0.04 M EDTA (pH 10.0). After washing with 5 ml of
0.02 M EDTA pH 10.0, radioactivity was measured in filters,
loading fraction, wash lysis fraction and EDTA wash. DNA frag-
mentation was determined as the fraction of 14C-labelled DNA in
the lysis fraction + EDTA wash relative to total intracellular 14C-
labelled DNA. Results are expressed as the percentage of DNA
fragmented in treated cells compared with the DNA fragmented in
control untreated cells (background) using the formula: [(F-FO) /
(1-FO)] x 100, where F and FO represent DNA fragmentation in
treated and control cells respectively.
RESULTS
Figure 1 reports the IC50 values calculated 72 h after 24-h exposure
to DDP. No clear correlation between the differential expression of
p53 and DDP-induced cytotoxicity was found. The figure also
shows a graphical representation of the same data where the lack
ofcorrelation between cytotoxicity and p53 status is more evident.
We also assessed the IC50 values of DDP in SKOV3-derived
clones obtained upon transfection with the temperature-sensitive
mutant murine p53 (clone SK23a) and again no differences could
be found.
We then used for each cell line, the calculated IC50 for DDP to
investigate the changes induced by the drug in the levels of p53
and p53-downstream genes (WAFI, GADD45 and bax).
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Figure 2 reports the western blot results, which indicate that
DDP treatment was able to induce a rise in p53 levels (measured
after 6 and 24 h oftreatment) in all the wt-p53-expressing cells. In
addition an increase in p53 levels was also observed in the mut-
p53-expressing OVCAR-3 cell line, while they were unaffected in
all the other mut-p53-expressing cell lines.
We then evaluated if the increase in p53 levels observed in the
wt-p53-expressing cell lines after DDP treatment resulted in an
increase in mRNA levels of WAF1, GADD45 and bax. Figure 3
reports the northern analysis in the four wt-p53-expressing cell
lines (Figure 3B) and in the five mut-p53-expressing cell lines
(Figure 3A). The relative increase over controls of the three
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Figure 5 mRNA expression of WAF1, GADD45 and bax in clones SKN and
SK23a treated with DDP at 370C or 320C. mRNA was extracted 1, 6 and 24 h
after treatment with DDP at the IC50 reported in Figure 1
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Figure 4 Relative increase in WAF1, GADD 45 and bax mRNAs induced by
DDP in the different human ovarian cancer cell lines. Northern blots reported
in Figure 3 were quantitated by densitometry and the data obtained were
plotted. For each cell line, the relative increase in mRNA over untreated cells
is reported
mRNAs measured by densitometric scanning of the autoradio-
graphs are reported in Figure 4.
As can be seen, in all the cell lines examined, DDP treatment
was able to increase the levels ofWAFI mRNAs independently of
the status of p53. GADD45 mRNA levels were also increased by
DDP, essentially with similarprofiles as those observed forWAF1;
this was with the exception of PA-1 and SW626 cells, in which
GADD45 levels were not increased. When tested by Westem blot-
ting, the levels of p21W Fl were also found to be increased after
DDP, in accordance with the mRNA levels (data not shown).
Bax mRNA levels were not increased to a similar extent and
only minor changes could be observed. It is interesting to note that
the most striking increase (relative to untreated cells) in bax
mRNA levels after DDP has been found in the mut-p53-
expressing cell line OVCAR-8.
We then analysed the WAF1, GADD45 and bax expression in
clones derived from SKOV3 cells after transfection with a temper-
ature-sensitive mutant murine p53. Figure 5 shows that when
SK23a cells were incubated at 32°C there was an increase in the
basal levels of WAF-l and GADD 45 mRNAs as a result of the
shift from the mutant to the wild-type form of p53 protein, while
bax levels were almost unmodified. In these clones, DDP was able
to induce an increase in WAFI and GADD45 and only slightly in
bax mRNAs. At 32°C, DDP was able to increase the levels of
WAFI and GADD45 in the mock-transfected SKN cells, while in
SK23a cells, in which the basal levels of WAFI and GADD45
were already increased by the presence of wt p53, DDP was
unable to further increase these mRNA levels.
DDP-induced apoptosis was investigated with two different
techniques. The DAPI staining was used to evaluate apoptosis in
cells treated with the IC50 calculated for DDP in each cell line,
while the filter-binding assay was used to evaluate DDP-induced
apoptosis at three different concentrations (1, 10 and 100 gM) for
all the cell lines examined.
Figure 6 shows representative pictures obtained after DAPI
staining in the different cell lines after 72 h of treatment with DDP.
The number of apoptotic cells was very low in the cells examined.
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Figure 6 DAPI staining of the different human ovarian cancer cell lines 72 h
after treatment with DDP at the IC50 reported in Figure 1
Similarresults were obtained atearlier(24 and48 h) times (data not
shown). A more quantitative assay (Table 1) was used to evaluate
the percentage of DNA fragmentation induced by DDP. As can
be seen, DDP-induced apoptosis was again generally greater in
wt-p53-expressing cells than in mut-p53-expressing cells but,
comparing the data with the IC5 values reported in Figure 1, it
appearsevidentthat atdoses close tothe DDPIC,thepercentage of
fragmentation was less then 20%, perhaps with the exception of
the A2774 cell line in which, at 10 ,UM DDP (the calculatedIC50 was
7.5 tM), the percentage ofDNA fragmentation was 69% at 72 h.
DISCUSSION
We report here evidence that DDP-induced cytotoxicity in ovarian
cancer cells in vitro is independent of the presence of a wt p53.
These results, obtained by using nine different human ovarian
cancer cell lines and clones obtained after transfection with mut or
wtp53, supportprevious results obtained in a limited number ofcell
lines but are in contrast with earlier reports ofa role ofp53 in deter-
mining cell sensitivity to DDP (Brown et al, 1993; Fan et al, 1995;
Gjerset et al, 1995; Graniela Sire et al, 1995; Vikhanskaya et al,
1995; Perego et al, 1996). The data reported here were obtained
using cells growing in vitro, acondition thatcouldnotbe completely
representative ofthe tumours from which they originate.
We previously reported similar conclusions by using the same
ovarian cancer cell lines treated with taxol (Debernardis et al,
1997) or clones derived from a human ovarian cancer cell line
treated with different DNA-damaging agents (Graniela Sire et al,
1995; Vikhanskaya et al, 1995). As in all the experimental condi-
tions drug-induced apoptosis was not significant, at least at the
doses close to the IC50, one can speculate that in conditions in
which apoptosis is not the major mechanism of cell death, as it
appears to be in ovarian cancer cells, p53 function does not play a
role in determining cytotoxicity. That this can be the case is also
supported by the evidence that DDP, as in the case of taxol
(Debernardis et al, 1997), is able to induce an increase in p53 that
is functional in terms oftranscriptional activation, asjudged by the
increase in WAFI and GADD45 mRNAs observed after treatment.
WAFI and GADD45 mRNAs induction by different stimuli in a
p53-independent way has already been reported (Michieli et al,
1994; Akashi et al, 1995; Vikhanskaya et al, 1995; Zeng et al,
1996). Interestingly, GADD45 andWAFI levels were increased by
DDP in mut-p53-expressing cells roughly to the same extent
observed in wt-p53-expressing cells.
It is interesting to note that bax levels were not strongly
increased after treatment with DDP in the cell lines examined, and
this is in agreement with data showing that GADD45 and WAFI
are much better substrates forp53 activation than bax (AC Hardy-
Bessard and T Soussi, personal communication). This could have
implications for the lack of a quantitatively important induction of
apoptosis in these ovarian cancer cells. It is still questionable
which role bax has in p53-induced apoptosis, but it is certainly not
the only factor responsible for this effect. Recent data support that,
Table 1 DNA fragmentation induced by DDP in different human ovarian cancer cell lines
Cell line DDP concentration (gM)
1 10 100
24h 48h 72h 24h 48h 72h 24h 48h 72h
OVCAR-3 1.5 0.5 0 2.0 9.5 24.0 7.0 15.0 19.0
OVCAR-5 0 1.0 2.5 0 7.5 12.0 0 3.0 9.0
OVCAR-8 0 0 2.0 0 4.5 4.5 27.0 28.0 38.0
SW626 0 0 0 0 0 0.5 0 0 0
SKOV-3 0 1.5 0 1.0 25.0 41.5 22.0 21.0 39.0
A2774 0 1.0 2.0 0 22.0 69.0 39.4 64.5 73.0
A2780 0.4 0 0.3 1.5 1.0 1.0 38.0 40.0 36.0
PA-1 2.0 11.0 21.0 19.0 75.0 35.0 75.0 60.0 48.0
IGROV-1 1.5 0 3.0 0 0 7.0 1.5 56.0 77.0
SK23a (370C) 0.4 1.2 4.4 5.2 26.3 38.0 33.4 23.0 22.9
SK23a (32°C) 0.5 1.6 0 0 3.5 8.1 2.5 10.1 14.9
SKN (37°C) 0.7 0 0.7 0.3 10.3 7.5 17.4 24.8 36.2
SKN (320C) 1.2 0 0.1 0.8 0 1.1 1.2 4.0 34.6
DNA fragmentation calculated as described in Materials and methods after 24, 48 or 72 h of treatment
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independently of the presence of p53, ectopic overexpression of
bax increases the sensitivity to anti-cancer drug treatment in vitro,
and this was associated with an increased fraction of apoptotic
cells after treatment (Sakakura et al, 1996; Wagener et al, 1996).
We have found anunexpected induction ofbax, although at very
low level, after DDP treatment in mut-p53-expressing cell lines.
This is a new finding, which deserves further, specifically
addressed experiments and which could support the existence of
new DNA damage and p53-independent activation ofbax.
In conclusion, ourdata show the independence ofDDP-induced
cytotoxicity from p53 status in ovarian cancer cell lines growing
in vitro.
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